Search Browse Earnings

Immuneering Corp — SlamSEC

Immuneering Corp

Nasdaq:IMRX

Pharmaceutical Preparations·CAMBRIDGE, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$316,952

-84.8% YoY

FY 2023

Adj. EBITDA

-$63.7M

-20102.6% margin

FY 2025

Net Income

-$61.0M

-19257.4% margin

FY 2025

EPS (Diluted)

-$2.04

FY 2025

Stock Price

$5.61

+5.3%

2026-03-09

52W Range

$1.10 – $10.08

P/E Ratio

-2.8x

Market Cap

$145.5M

Cash

$36.1M

FY 2025

Total Debt

—

Net Cash

$36.1M

FY 2023

Enterprise Value

$109.4M

Debt / EBITDA

0.6x

FY 2023

EV / EBITDA

-1.7x

Employees

—

CEO

Zeskind Benjamin J.